Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (Sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy

Enriched recordOpen access

Allan J. Pantuck, Nazy Zomorodian, Arie S. Belldegrun

Abstract

No public abstract is available from the verified source records.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

No local reference links have been materialized yet.

No local citing links have been materialized yet.

Unresolved referenced work

2004

10.1001/jama.280.11.969

10.1001/jama.280.11.969 · 1998

10.1200/jco.1999.17.5.1499

10.1200/jco.1999.17.5.1499 · 1999

10.1016/s0022-5347(05)66349-5

10.1016/s0022-5347(05)66349-5 · 2001

10.1016/s0022-5347(17)32397-2

10.1016/s0022-5347(17)32397-2 · 1994

No additional external references are available.